Oncology News Today

30/04/2026

📰 NEWS: A multi-million pound University of Dundee study, in collaboration with a research centre in Germany, intends to reveal the workings of cellular “light switches” that are a potential cause of cancer.

Image: Professor Adrian Saurin. Credit: University of Dundee.

Read more:

A multi-million pound University of Dundee study, in collaboration with a research centre in Germany, intends to reveal the workings of cellular “light switches” that are a potential cause of cancer.

29/04/2026

📰 NEWS: Trinity College, Cambridge Fellow and Head of Oncology at Cambridge Professor Rebecca Fitzgerald and colleagues at the Li Ka Shing Early Cancer Institute have confirmed that Barrett’s oesophagus is the genesis of the most common type of oesophageal cancer in the developed world.

Their research published in Nature Medicine could help improve the early detection of oesophageal cancer, which is often diagnosed at an advanced staged when treatment options are limited.

Read more:

Trinity College Fellow and Head of Oncology at Cambridge Professor Rebecca Fitzgerald and colleagues at the Li Ka Shing Early Cancer Institute have confirmed that Barrett’s oesophagus is the genesis of the most common type of oesophageal cancer in the developed world.

28/04/2026

📰 NEWS: Patients with a specific type of bowel cancer who were treated with a short course of immunotherapy before surgery instead of post-op chemotherapy have remained cancer-free after almost three years of follow-up, according to new results from the NEOPRISM-CRC clinical trial led by a team from UCL and UCLH - University College London Hospitals NHS Foundation Trust.

The latest findings, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, build on earlier results showing that nine weeks of pre-operative immunotherapy using the drug pembrolizumab led to major tumour shrinkage in patients with stage two or three bowel cancer.

Initial results indicated that 59 per cent of patients had no signs of disease after treatment with pembrolizumab and their planned bowel cancer operation.

Now 33 months later, none of the treated patients have experienced a return of their cancer. This includes those who had no signs of cancer after treatment and those who still had small amounts remaining, which did not grow or spread during follow-up.

Read more:

Patients with a specific type of bowel cancer who were treated with a short course of immunotherapy before surgery instead of post-op chemotherapy have remained cancer-free after almost three years of follow-up, according to new results from the NEOPRISM-CRC clinical trial led by a team from UCL and...

24/04/2026

📰 NEWS: Data from the Clatterbridge Cancer Centre NHS Foundation Trust patients has been used in research that could change UK clinical practice in prostate cancer care.

This major national study has shown that artificial intelligence can significantly improve predictions about how a patient’s prostate cancer is likely to behave.

The findings come from biopsies taken in the CHHiP clinical trial from hundreds of men treated for localised prostate cancer at The Clatterbridge Cancer Centre between 2002 and 2011, and their health monitored for more than 10 years afterwards.

Read more:

Data from Clatterbridge Cancer Centre NHS Foundation Trust patients has been used in research that could change UK clinical practice in prostate cancer care.

23/04/2026

📰 NEWS: Prostate Cancer Research has announced £1.3m funding for another round of groundbreaking research to investigate why prostate cancer hits Black men harder and tackle the racial inequities experienced by Black communities.

Read more:

Leading UK charity Prostate Cancer Research has announced £1.3 million funding for another round of groundbreaking research to investigate why prostate cancer hits Black men harder and tackle the stark racial inequities experienced by Black communities.

23/04/2026

❗️ JOB ALERT: Health New Zealand - Te Whatu Ora is seeking Radiation Oncologists from the UK and Ireland to join multidisciplinary cancer services across New Zealand.

Working as a Radiation Oncologist in New Zealand offers a unique work-life balance in a clean, green, and safe environment. The country's healthcare system, particularly in Oncology, is recognised for its high standards and patient-centred care.

Radiation Oncologists have access to modern equipment and advanced technologies such as IMRT (Intensity-Modulated Radiation Therapy) and SBRT (Stereotactic Body Radiation Therapy).

APPLY NOW: https://oncologynewstoday.co.uk/jobs/radiation-oncologists-2/

22/04/2026

📰 NEWS: New ground-breaking brain cancer clinical trials designed to improve survival and quality of life for the most common type of brain cancer are starting in Yorkshire.

Funded by Yorkshire Cancer Research, EPIC-GB, a £6.9 million programme of clinical trials led by experts at The University of Sheffield and the University of Glasgow, aim to transform how cancer drug treatments are tested for people with recurrent glioblastoma, so they can access new and potentially life-extending treatment options.

The programme will be co-led by Mr Ola Rominiyi (pictured), Neurological Resident at Sheffield Teaching Hospitals NHS Foundation Trust.

Read more: https://oncologynewstoday.co.uk/brain-cancer-clinical-trials-aim-to-bring-hope/

Pictured: Mr Ola Rominiyi, Neurological Resident

New ground-breaking brain cancer clinical trials designed to improve survival and quality of life for the most common type of brain cancer are starting in Yorkshire.

21/04/2026

📰 NEWS: The Royal Marsden has announced the launch of MyTrack Myeloma, the world’s first fully integrated patient pathway for multiple myeloma.

This innovative, patient-centred approach brings together leading-edge innovation in advanced diagnostics and clinical expertise to transform how multiple myeloma is understood, monitored, managed and treated, with the goal of significantly improving the patient experience.

Read more: https://oncologynewstoday.co.uk/the-royal-marsden-launches-worlds-first-fully-integrated-multiple-myeloma-patient-pathway/

Pictured: Professor Martin Kaiser (pictured), Consultant Haematologist at The Royal Marsden NHS Foundation Trust and Professor in Molecular Haematology at The Institute of Cancer Research, London

21/04/2026

❗️ JOB ALERT: Health New Zealand - Te Whatu Ora is seeking Medical Oncologists from the UK & Ireland to deliver high-quality systemic cancer care within hospital-based teams across New Zealand.

With an emphasis on collaboration between primary, secondary, and tertiary care, Medical Oncologists work closely with Surgeons, Radiologists, Pathologists, and Nurses to achieve the best outcomes for patients.

https://oncologynewstoday.co.uk/jobs/medical-oncologists-2/

20/04/2026

📰 NEWS: First targeted oral treatment approved by NICE for patients with Grade 2 glioma in the UK

Thanks to the contribution of patients and researchers at The Royal Marsden NHS Foundation Trust, patients in the UK with Grade 2 glioma, a slow-growing but progressive brain tumour, could benefit from a newly approved targeted therapy.

The drug received approval from the National Institute for Health and Care Excellence (NICE) on March 31 and is now available to patients on the NHS in England.

Declan (pictured), 28, a glioma patient at The Royal Marsden, started taking vorasidenib last year and his tumour has remained stable since being on the treatment.

He said: “Last year, while on holiday in Kenya with my girlfriend, I suddenly had a seizure. It was a huge shock as until that moment, I’d felt completely fine. Back in the UK, I had surgery, but they discovered my tumour had likely been there for a number of years. Because of this, my brain had adapted around it and removing more than five per cent of the tumour would affect my ability to speak. The surgery was done while I was awake and I struggled to speak for three or four months afterwards, needing intensive speech therapy.

“Following the surgery, I started taking vorasidenib and my tumour has remained stable since being on the treatment. I try to stay positive. The care I’ve received at The Royal Marsden has been exceptional.”

Read more:

Thanks to the contribution of patients and researchers at The Royal Marsden NHS Foundation Trust, patients in the UK with Grade 2 glioma, a slow-growing but progressive brain tumour, could benefit from a newly approved targeted therapy.

17/04/2026

Considering a career as a Cancer Clinical Nurse Specialist?

Join the South East London Cancer Alliance NHS's webinar exploring the role, offering targeted guidance, education and career support.

🗓️ Wednesday, April 22
⏰ 12:30 PM - 1:30 PM
📍 Online

This is the fifth in a series of webinars, each covering a different topic to equip you with the insights, information, and inspiration you need to start considering a career as a Cancer CNS.

Find out more: https://oncologynewstoday.co.uk/event/start-your-journey-in-cancer-nursing-exploring-the-cns-role/

To provide targeted guidance, education, and career support for nurses considering a career as a Cancer Clinical Nurse Specialist (CNS).

17/04/2026

📰 NEWS: A patient at Barts Health NHS Trust is the first in the NHS to have lung cancer surgery using the newest robotic surgical technology.

The operation was carried out at St Bartholomew’s Hospital using the dual console da Vinci 5 Surgical System, developed by Intuitive. The milestone marks the next stage in Barts Health’s long-established robotic-assisted surgery programme, with thousands of patients benefitting to date.

Sasha Stamenkovic, consultant thoracic surgeon and director of robotic surgery, said: “Being the first centre in the UK to use this system for thoracic surgery reflects the strength of our clinical teams, our commitment to innovation, and our focus on delivering the very best outcomes for patients, while strengthening our role as a national and international centre for training and research.”

Read more: https://oncologynewstoday.co.uk/nhs-first-as-barts-patient-treated-with-new-surgical-robot/

Pictured: The surgical team

NHS UK

A patient at Barts Health NHS Trust is the first in the NHS to have lung cancer surgery using the newest robotic surgical technology.